Aquaculture Vaccines Market - By Type of Vaccines, By Route of Administration, By Application, By Species & Global Forecast, 2023

Description

List of Tables

Global Aquaculture Vaccines Market is anticipated to witness massive growth through 2032, propelled by new R&D initiatives undertaken by key players to develop novel and advanced aquaculture vaccines. As a result, the industry is expected to experience significant growth in the coming years as more and more products are being introduced globally. In addition, the government-imposed restrictions on the sale of antibiotics in some industrialized countries will also contribute to the expansion of the aquaculture vaccine market during 2023-2032.

The process of creating vaccines with many antigens is complicated. Moreover, the lack of public acceptance further restricts the vaccine development process and production activities, slowing the market expansion. However, the proven benefits of vaccinating fish in alleviating the undesirable side effects of antibiotics and offering protection against viral and bacterial diseases are expected to boost the aquaculture vaccine industry growth in the future in the forthcoming years.

Overall, the aquaculture vaccines industry is segregated in terms of types of vaccines, route of administration, application, species, and regional landscape.

With respect to vaccines, the live vaccine segment share is expected to grow exponentially between 2023 and 2032. The growth will be accredited to the numerous clinical findings pointing toward the benefits of live vaccines, such as cost-effective production, ease of culture, clear genetic background, etc.

By route of administration, the oral vaccine segment is poised to experience strong growth owing to the numerous advantages associated with oral vaccines. These vaccines can significantly enhance fish immunity and require less stress and simple administration. Additionally, the growing popularity of aquaculture farming and the prevalence of infectious diseases in various fish species will further drive the demand for oral vaccines and support the market expansion through 2032.

Regarding the application spectrum, the bacterial infection segment is envisioned to expand appreciably over the coming ten years owing to the surging incidences of bacterial infections in various fish species. Besides, the increasing rollouts of several government-backed initiatives and awareness programs focused on alleviating the spread of bacterial infections in aquaculture animals will drive lucrative gains to the aquaculture vaccine business.

In terms of species, the trout segment is anticipated to grow at more than 7.5% CAGR by 2032. It is a leading aspect of aquaculture in regions such as North America, Japan, Europe, Chile, and Australia. In addition, several health benefits, including better skin health, improved metabolism, and cpntrolled hypertension offered by trout are expected to escalate the demand for vaccines to prevent infections in trout fish and increase productivity, thereby boosting segment growth.

Regionally, the North America aquaculture vaccines market garnered revenues worth over USD 20 million in 2022 and is slated to register massive growth by 2032 owing to the surging R&D investments by leading market players in the region.

Product Code: 3323

Chapter 1 Methodology

1.1 Methodology
1.2 Market scope and definition
1.3 Base estimates & calculations
1.4 Forecast calculations
1.5 Data sources
1.6 Primary
- 1.6.1 Secondary
  - 1.6.1.1 Paid sources
  - 1.6.1.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Aquaculture Vaccines industry 360 degree synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Type of vaccines trends
- 2.1.3 Route of administration trends
- 2.1.4 Application trends
- 2.1.5 Species trends
- 2.1.6 Regional trends

Chapter 3 Aquaculture Vaccines Industry Insights

3.1 Industry ecosystem analysis
3.2 Vendor matrix
3.3 Industry impact factors
- 3.3.1 Growth drivers
  - 3.3.1.1 Surging prevalence of bacterial and viral infections
  - 3.3.1.2 Increasing aquaculture production across the globe
  - 3.3.1.3 Development and launch of new aquaculture vaccines
  - 3.3.1.4 Rising adoption of aquaculture vaccines over antibiotics
- 3.3.2 Industry pitfalls & challenges
  - 3.3.2.1 Stringent regulatory policies for vaccine approval
  - 3.3.2.2 Complex vaccine development procedures
3.4 Growth potential analysis
- 3.4.1 By type of vaccines
- 3.4.2 By route of administration
- 3.4.3 By application
- 3.4.4 By species
3.5 Regulatory scenario
- 3.5.1 U.S.
- 3.5.2 Canada
- 3.5.3 Europe
3.6 Porter's analysis
- 3.6.1 Industry rivalry
- 3.6.2 Buyer power
- 3.6.3 Supplier power
- 3.6.4 Threat of substitute
- 3.6.5 Threat of new entrants
3.7 PESTEL analysis
- 3.7.1 Political
- 3.7.2 Economical
- 3.7.3 Social
- 3.7.4 Technological
- 3.7.5 Environmental
- 3.7.6 Legal

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Product portfolio matrix
- 4.2.1 Zoetis Inc.
- 4.2.2 Merck & Co., Inc.
- 4.2.3 HIPRA
- 4.2.4 Tecnovax
- 4.2.5 Virbac
- 4.2.6 Veterquimica S.A.
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic outlook matrix

Chapter 5 Aquaculture Vaccines Market, By Type of vaccines

5.1 Key segment trends
5.2 Inactivated vaccines
- 5.2.1 Market size, by region, 2018 - 2032 (USD Million)
5.3 Live vaccines
- 5.3.1 Market size, by region, 2018 - 2032 (USD Million)

Chapter 6 Aquaculture Vaccines Market, By Route of Administration

6.1 Key segment trends
6.2 Immersion vaccines
- 6.2.1 Market size, by region, 2018 - 2032 (USD Million)
6.3 Injection vaccines
- 6.3.1 Market size, by region, 2018 - 2032 (USD Million)
6.4 Oral vaccines
- 6.4.1 Market size, by region, 2018 - 2032 (USD Million)

Chapter 7 Aquaculture Vaccines Market, By Application

7.1 Key segment trends
7.2 Bacterial infection
- 7.2.1 Market size, by region, 2018 - 2032 (USD Million)
7.3 Viral Infection
- 7.3.1 Market size, by region, 2018 - 2032 (USD Million)
7.4 Others
- 7.4.1 Market size, by region, 2018 - 2032 (USD Million)

Chapter 8 Aquaculture Vaccines Market, By Species

8.1 Key segment trends
8.2 Salmon
- 8.2.1 Market size, by region, 2018 - 2032 (USD Million)
8.3 Trout
- 8.3.1 Market size, by region, 2018 - 2032 (USD Million)
8.4 Tilapia
- 8.4.1 Market size, by region, 2018 - 2032 (USD Million)
8.5 Others
- 8.5.1 Market size, by region, 2018 - 2032 (USD Million)

Chapter 9 Aquaculture Vaccines Market, By Region

9.1 Key regional trends
9.2 North America
- 9.2.1 Market size, by country, 2018 - 2032
- 9.2.2 Market size, by type of vaccines, 2018 - 2032
- 9.2.3 Market size, by route of administration, 2018 - 2032
- 9.2.4 Market size, by application, 2018 - 2032
- 9.2.5 Market size, by species, 2018 - 2032
- 9.2.2 U.S.
  - 9.2.2.1 Market size, by type of vaccines, 2018 - 2032
  - 9.2.2.2 Market size, by route of administration, 2018 - 2032
  - 9.2.2.3 Market size, by application, 2018 - 2032
  - 9.2.2.4 Market size, by species, 2018 - 2032
- 9.2.3 Canada
  - 9.2.3.1 Market size, by type of vaccines, 2018 - 2032
  - 9.2.3.2 Market size, by route of administration, 2018 - 2032
  - 9.2.3.3 Market size, by application, 2018 - 2032
  - 9.2.3.4 Market size, by species, 2018 - 2032
9.3 Europe
- 9.3.1 Market size, by country, 2018 - 2032
- 9.3.2 Market size, by type of vaccines, 2018 - 2032
- 9.3.3 Market size, by route of administration, 2018 - 2032
- 9.3.4 Market size, by application, 2018 - 2032
- 9.3.5 Market size, by species, 2018 - 2032
- 9.3.2 Germany
  - 9.3.2.1 Market size, by type of vaccines, 2018 - 2032
  - 9.3.2.2 Market size, by route of administration, 2018 - 2032
  - 9.3.2.3 Market size, by application, 2018 - 2032
  - 9.3.2.4 Market size, by species, 2018 - 2032
- 9.3.3 UK
  - 9.3.3.1 Market size, by type of vaccines, 2018 - 2032
  - 9.3.3.2 Market size, by route of administration, 2018 - 2032
  - 9.3.3.3 Market size, by application, 2018 - 2032
  - 9.3.3.4 Market size, by species, 2018 - 2032
- 9.3.4 France
  - 9.3.4.1 Market size, by type of vaccines, 2018 - 2032
  - 9.3.4.2 Market size, by route of administration, 2018 - 2032
  - 9.3.4.3 Market size, by application, 2018 - 2032
  - 9.3.4.4 Market size, by species, 2018 - 2032
- 9.3.5 Spain
  - 9.3.5.1 Market size, by type of vaccines, 2018 - 2032
  - 9.3.5.2 Market size, by route of administration, 2018 - 2032
  - 9.3.5.3 Market size, by application, 2018 - 2032
  - 9.3.5.4 Market size, by species, 2018 - 2032
- 9.3.6 Italy
  - 9.3.6.1 Market size, by type of vaccines, 2018 - 2032
  - 9.3.6.2 Market size, by route of administration, 2018 - 2032
  - 9.3.6.3 Market size, by application, 2018 - 2032
  - 9.3.6.4 Market size, by species, 2018 - 2032
- 9.3.7 Norway
  - 9.3.7.1 Market size, by type of vaccines, 2018 - 2032
  - 9.3.7.2 Market size, by route of administration, 2018 - 2032
  - 9.3.7.3 Market size, by application, 2018 - 2032
  - 9.3.7.4 Market size, by species, 2018 - 2032
- 9.3.8 Ireland
  - 9.3.8.1 Market size, by type of vaccines, 2018 - 2032
  - 9.3.8.2 Market size, by route of administration, 2018 - 2032
  - 9.3.8.3 Market size, by application, 2018 - 2032
  - 9.3.8.4 Market size, by species, 2018 - 2032
- 9.3.9 Turkey
  - 9.3.9.1 Market size, by type of vaccines, 2018 - 2032
  - 9.3.9.2 Market size, by route of administration, 2018 - 2032
  - 9.3.9.3 Market size, by application, 2018 - 2032
  - 9.3.9.4 Market size, by species, 2018 - 2032
- 9.3.10 Denmark
  - 9.3.10.1 Market size, by type of vaccines, 2018 - 2032
  - 9.3.10.2 Market size, by route of administration, 2018 - 2032
  - 9.3.10.3 Market size, by application, 2018 - 2032
  - 9.3.10.4 Market size, by species, 2018 - 2032
9.4 Asia Pacific
- 9.4.1 Market size, by country, 2018 - 2032
- 9.4.2 Market size, by type of vaccines, 2018 - 2032
- 9.4.3 Market size, by route of administration, 2018 - 2032
- 9.4.4 Market size, by application, 2018 - 2032
- 9.4.5 Market size, by species, 2018 - 2032
- 9.4.2 China
  - 9.4.2.1 Market size, by type of vaccines, 2018 - 2032
  - 9.4.2.2 Market size, by route of administration, 2018 - 2032
  - 9.4.2.3 Market size, by application, 2018 - 2032
  - 9.4.2.4 Market size, by species, 2018 - 2032
- 9.4.3 Indonesia
  - 9.4.3.1 Market size, by type of vaccines, 2018 - 2032
  - 9.4.3.2 Market size, by route of administration, 2018 - 2032
  - 9.4.3.3 Market size, by application, 2018 - 2032
  - 9.4.3.4 Market size, by species, 2018 - 2032
- 9.4.4 Philippines
  - 9.4.4.1 Market size, by type of vaccines, 2018 - 2032
  - 9.4.4.2 Market size, by route of administration, 2018 - 2032
  - 9.4.4.3 Market size, by application, 2018 - 2032
  - 9.4.4.4 Market size, by species, 2018 - 2032
- 9.4.5 Thailand
  - 9.4.5.1 Market size, by type of vaccines, 2018 - 2032
  - 9.4.5.2 Market size, by route of administration, 2018 - 2032
  - 9.4.5.3 Market size, by application, 2018 - 2032
  - 9.4.5.4 Market size, by species, 2018 - 2032
- 9.4.6 Australia
  - 9.4.6.1 Market size, by type of vaccines, 2018 - 2032
  - 9.4.6.2 Market size, by route of administration, 2018 - 2032
  - 9.4.6.3 Market size, by application, 2018 - 2032
  - 9.4.6.4 Market size, by species, 2018 - 2032
- 9.4.7 New Zealand
  - 9.4.7.1 Market size, by type of vaccines, 2018 - 2032
  - 9.4.7.2 Market size, by route of administration, 2018 - 2032
  - 9.4.7.3 Market size, by application, 2018 - 2032
  - 9.4.7.4 Market size, by species, 2018 - 2032
9.5 Latin America
- 9.5.1 Market size, by country, 2018 - 2032
- 9.5.2 Market size, by type of vaccines, 2018 - 2032
- 9.5.3 Market size, by route of administration, 2018 - 2032
- 9.5.4 Market size, by application, 2018 - 2032
- 9.5.5 Market size, by species, 2018 - 2032
- 9.5.2 Brazil
  - 9.5.2.1 Market size, by type of vaccines, 2018 - 2032
  - 9.5.2.2 Market size, by route of administration, 2018 - 2032
  - 9.5.2.3 Market size, by application, 2018 - 2032
  - 9.5.2.4 Market size, by species, 2018 - 2032
- 9.5.3 Mexico
  - 9.5.3.1 Market size, by type of vaccines, 2018 - 2032
  - 9.5.3.2 Market size, by route of administration, 2018 - 2032
  - 9.5.3.3 Market size, by application, 2018 - 2032
  - 9.5.3.4 Market size, by species, 2018 - 2032
- 9.5.4 Chile
  - 9.5.4.1 Market size, by type of vaccines, 2018 - 2032
  - 9.5.4.2 Market size, by route of administration, 2018 - 2032
  - 9.5.4.3 Market size, by application, 2018 - 2032
  - 9.5.4.4 Market size, by species, 2018 - 2032
9.6 MEA
- 9.6.1 Market size, by country, 2018 - 2032
- 9.6.2 Market size, by type of vaccines, 2018 - 2032
- 9.6.3 Market size, by route of administration, 2018 - 2032
- 9.6.4 Market size, by application, 2018 - 2032
- 9.6.5 Market size, by species, 2018 - 2032
- 9.6.2 Iran
  - 9.6.2.1 Market size, by type of vaccines, 2018 - 2032
  - 9.6.2.2 Market size, by route of administration, 2018 - 2032
  - 9.6.2.3 Market size, by application, 2018 - 2032
  - 9.6.2.4 Market size, by species, 2018 - 2032
- 9.6.3 Egypt
  - 9.6.3.1 Market size, by type of vaccines, 2018 - 2032
  - 9.6.3.2 Market size, by route of administration, 2018 - 2032
  - 9.6.3.3 Market size, by application, 2018 - 2032
  - 9.6.3.4 Market size, by species, 2018 - 2032

Chapter 10 Company Profiles

10.1 Hipra
- 10.1.1 Business overview
- 10.1.2 Financial data
- 10.1.3 Product landscape
- 10.1.4 Strategic outlook
- 10.1.5 SWOT analysis
10.2 Zoetis Inc.
- 10.2.1 Business overview
- 10.2.2 Financial data
- 10.2.3 Product landscape
- 10.2.4 Strategic outlook
- 10.2.5 SWOT analysis
10.3 Merck & Co., Inc.
- 10.3.1 Business overview
- 10.3.2 Financial data
- 10.3.3 Product landscape
- 10.3.4 Strategic outlook
- 10.3.5 SWOT analysis
10.4 Tecnovax
- 10.4.1 Business overview
- 10.4.2 Financial data
- 10.4.3 Product landscape
- 10.4.4 Strategic outlook
- 10.4.5 SWOT analysis
10.5 Virbac
- 10.5.1 Business overview
- 10.5.2 Financial data
- 10.5.3 Product landscape
- 10.5.4 Strategic outlook
- 10.5.5 SWOT analysis
10.6 Veterquimica S.A.
- 10.6.1 Business overview
- 10.6.2 Financial data
- 10.6.3 Product landscape
- 10.6.4 Strategic outlook
- 10.6.5 SWOT analysis
10.7 Nisseiken Co. Ltd.
- 10.7.1 Business overview
- 10.7.2 Financial data
- 10.7.3 Product landscape
- 10.7.4 Strategic outlook
- 10.7.5 SWOT analysis
10.8 Phibro Animal Health Corporation
- 10.8.1 Business overview
- 10.8.2 Financial data
- 10.8.3 Product landscape
- 10.8.4 Strategic outlook
- 10.8.5 SWOT analysis
10.9 Vaxxinova International BV
- 10.9.1 Business overview
- 10.9.2 Financial data
- 10.9.3 Product landscape
- 10.9.4 Strategic outlook
- 10.9.5 SWOT analysis
10.10 Kyoto Biken Laboratories, Inc
- 10.10.1 Business overview
- 10.10.2 Financial data
- 10.10.3 Product landscape
- 10.10.4 Strategic outlook
- 10.10.5 SWOT analysis